We are (1R,2R)-(-)-1,2-Diaminocyclohexane CAS:20439-47-8 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: (1R,2R)-(-)-1,2-Diaminocyclohexane
Molecular Formula: C6H14N2
Physical and Chemical Properties:
Boiling point: 86-88 ° C 23mm
Melting point: 41-45 ° C
Flash point: 76 ºC
Refractive index: 1.484
Appearance:White Crystalline Powder
Moisture Content: Not more than 1.0%
Impurity: Not more than 2.0%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Intermediates of Oxaliplatin CAS:61825-94-3
Related News: The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels.N-(4-Methylphenyl)-3-oxobutanamide CAS:2415-82-9 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.1313900-20-7 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.2740-81-0 Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.